ML347BMP receptor inhibitor,potent and selective CAS# 1062368-49-3 |
- LDN193189 Hydrochloride
Catalog No.:BCC1695
CAS No.:1062368-62-0
- ASP3026
Catalog No.:BCC1372
CAS No.:1097917-15-1
- AP26113
Catalog No.:BCC1069
CAS No.:1197958-12-5
- CH5424802
Catalog No.:BCC3749
CAS No.:1256580-46-7
- ALK inhibitor 2
Catalog No.:BCC1340
CAS No.:761438-38-4
- (R)-Crizotinib
Catalog No.:BCC1284
CAS No.:877399-52-5
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 1062368-49-3 | SDF | Download SDF |
| PubChem ID | 44577753 | Appearance | Powder |
| Formula | C22H16N4O | M.Wt | 352.39 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | LDN 193719, 1lWY, VU0469381 | ||
| Solubility | DMSO : 6.2 mg/mL (17.59 mM; Need ultrasonic) | ||
| Chemical Name | 5-[6-(4-methoxyphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]quinoline | ||
| SMILES | COC1=CC=C(C=C1)C2=CN3C(=C(C=N3)C4=C5C=CC=NC5=CC=C4)N=C2 | ||
| Standard InChIKey | FVRYPYDPKSZGNS-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C22H16N4O/c1-27-17-9-7-15(8-10-17)16-12-24-22-20(13-25-26(22)14-16)18-4-2-6-21-19(18)5-3-11-23-21/h2-14H,1H3 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Potent and selective ALK2 and ALK1 inhibitor (IC50 values are 32 and 46 nM, respectively); displays >200 fold selectivity over ALK3 and ALK6 and >400 fold selectivity over VEGF2. Exhibits no activity at ALK4, ALK5 or in a panel of related kinases. Inhibits BMP4 signaling in a functional assay (IC50 = 152 nM). |
ML347 Dilution Calculator
ML347 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.8378 mL | 14.1888 mL | 28.3776 mL | 56.7553 mL | 70.9441 mL |
| 5 mM | 0.5676 mL | 2.8378 mL | 5.6755 mL | 11.3511 mL | 14.1888 mL |
| 10 mM | 0.2838 mL | 1.4189 mL | 2.8378 mL | 5.6755 mL | 7.0944 mL |
| 50 mM | 0.0568 mL | 0.2838 mL | 0.5676 mL | 1.1351 mL | 1.4189 mL |
| 100 mM | 0.0284 mL | 0.1419 mL | 0.2838 mL | 0.5676 mL | 0.7094 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
ML347 is a potent and selective inhibitor of bone morphogenetic protein (BMP) receptor with IC50 value of 32nM against ALK2 [1].
ML347 is discovered as a selective inhibitor of BMP type-I receptor ALK2 versus ALK3 and is identified as a probe molecule. In the in vitro kinase assay, ML347 shows potent inhibitory activities against ALK1 and ALK2 with IC50 values of 46 and 32 nM, respectively. The IC50 value of it for ALK3 is more than 10μM, demonstrating that ML347 is 300-fold more potent against ALK2. Besides that, ML347 exerts no inhibition effect on other related kinases such as ALK6 and KDR. Moreover, ML347 also shows effective inhibition with IC50 value of 152nM in the BMP4 cell based assay using C2C12BRA cells [1].
References:
[1] Engers D W, Frist A Y, Lindsley C W, et al. Synthesis and structure–activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo [1.5-a] pyrimidine scaffold of Dorsomorphin: The discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorganic & medicinal chemistry letters, 2013, 23(11): 3248-3252.
- LDN-193189
Catalog No.:BCC3687
CAS No.:1062368-24-4
- Ro3280
Catalog No.:BCC3962
CAS No.:1062243-51-9
- WYE-354
Catalog No.:BCC1059
CAS No.:1062169-56-5
- WYE-687
Catalog No.:BCC4604
CAS No.:1062161-90-3
- WAY-600
Catalog No.:BCC4607
CAS No.:1062159-35-6
- TC-G 1004
Catalog No.:BCC6165
CAS No.:1061747-72-5
- PND-1186
Catalog No.:BCC1866
CAS No.:1061353-68-1
- Senktide
Catalog No.:BCC6921
CAS No.:106128-89-6
- Hoechst 33342 analog 2
Catalog No.:BCC1631
CAS No.:106050-84-4
- Palmatine hydrochloride
Catalog No.:BCN5914
CAS No.:10605-02-4
- β-Interleukin I (163-171), human
Catalog No.:BCC1017
CAS No.:106021-96-9
- Nerol
Catalog No.:BCN8517
CAS No.:106-25-2
- LDN193189 Hydrochloride
Catalog No.:BCC1695
CAS No.:1062368-62-0
- Thioperamide
Catalog No.:BCC6734
CAS No.:106243-16-7
- 4-[(4-Methylpiperazin-1-yl) methyl]benzoic acid dihydrochloride
Catalog No.:BCC8669
CAS No.:106261-49-8
- Risperidone
Catalog No.:BCC3850
CAS No.:106266-06-2
- Sikokianin A
Catalog No.:BCN3133
CAS No.:106293-99-6
- Nomilin
Catalog No.:BCN1034
CAS No.:1063-77-0
- Rufinamide
Catalog No.:BCC5078
CAS No.:106308-44-5
- DAPTA
Catalog No.:BCC5909
CAS No.:106362-34-9
- ω-Conotoxin GVIA
Catalog No.:BCC5700
CAS No.:106375-28-4
- Boc-D-Alaninol
Catalog No.:BCC2727
CAS No.:106391-86-0
- Boc-D-Valinol
Catalog No.:BCC2692
CAS No.:106391-87-1
- Deoxymorellin
Catalog No.:BCN3067
CAS No.:1064-34-2
Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe.[Pubmed:23639540]
Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52.
A structure-activity relationship of the 3- and 6-positions of the pyrazolo[1,5-a]pyrimidine scaffold of the known BMP inhibitors dorsomorphin, 1, LDN-193189, 2, and DMH1, 3, led to the identification of a potent and selective compound for ALK2 versus ALK3. The potency contributions of several 3-position substituents were evaluated with subtle structural changes leading to significant changes in potency. From these studies, a novel 5-quinoline molecule was identified and designated an MLPCN probe molecule, ML347, which shows >300-fold selectivity for ALK2 and presents the community with a selective molecular probe for further biological evaluation.
